ProfileGDS5678 / 1430520_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 48% 55% 50% 49% 50% 48% 71% 49% 49% 49% 49% 49% 52% 49% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1963948
GSM967853U87-EV human glioblastoma xenograft - Control 23.371755
GSM967854U87-EV human glioblastoma xenograft - Control 33.1832350
GSM967855U87-EV human glioblastoma xenograft - Control 43.1024149
GSM967856U87-EV human glioblastoma xenograft - Control 53.1428550
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2394848
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4464671
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1563949
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.155949
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1467949
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1557849
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1290849
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2601552
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1518749